Q2
WST — Q2 2026 Financial Report Analysis
West's Q2 2026 sales rose 13.8% to $872.3M and diluted EPS 18.1% to $2.15, led by 29% organic growth in biologics/GLP-1 components; full-year guidance was raised, but Q3 reported growth is guided to just 2–4% as the SmartDose line exits.